Pubblicazioni

    Elenco pubblicazioni su riviste Internazionali Peer-Review

     

    1. Morari M, Sbrenna S, Marti M, Caliari F, Bianchi C and Beani L (1998) NMDA and non-NMDA ionotropic glutamate receptors modulate striatal acetylcholine release via pre- and postsynaptic mechanisms. J. Neurochem. 71, 2006-2017. (IF= 4,651; Q1)
    2. Morari M, Marti M, Sbrenna S, Fuxe K, Bianchi C and Beani L (1998) Reciprocal dopamine-glutamate modulation of release in the basal ganglia. Neurochem. Int. 33, 383-397. (IF= 1,781; Q2)
    3. Morari M, Sbrenna S, Marti M, O’ Connor WT, Bianchi C, Fuxe K and Beani L (1998) Evidence for a striatal NMDA receptor modulation of the nigral glutamate release. A dual probe microdyalisis study in the awake freely moving rat. Eur. J. Neurosci. 10, 1716-1722. (IF= 3,82; Q2)
    4. Marti M, Sbrenna S, Fuxe K, Bianchi C, Beani L and Morari M (1999) In vitro evidence for increased facilitation of striatal acetylcholine release via pre- and postsynaptic NMDA receptors in hemiparkinsonian rats. J. Neurochem. 72, 875-878. (IF= 4,906; Q1)
    5. Sbrenna S, Marti M, Morari M, Calò G, Guerrini R, Beani L and Bianchi C (1999) L-glutamate and gamma-aminobutyric acid efflux from rat cerebrocortical synaptosomes: modulation by kappa- and mu- but not delta- and opioid receptor like-1 receptors. J. Pharmacol. Exp. Ther. 291,1365-1371. (IF= 3.3; Q1)
    6. Marti M, Bregola G, Morari M, Gemignani A and Simonato M (2000) Somatostatin release in the hippocampus in the kindling model of epilespy: a microdialysis study. J. Neurochem. 74, 2497-2503. (IF= 4,9; Q1)
    7. Marti M, Sbrenna S, Fuxe K, Bianchi C, Beani L and Morari M (2000) Increased responsitivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats. Eur. J. Neurosci. 12, 1848-1850. (IF= 3,862; Q2)
    8. Sbrenna S, Marti M, Morari M, Calò G, Guerrini R, Beani L and Bianchi C (2000) Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin. Br J. Pharmacol. 130, 425-433. (IF= 3,689; Q1)
    9. Marti M, Bregola G, Binaschi A, Gemignani A and Simonato M (2000) Kindling seizure-evoked somatostatin release in the hippocampus: inhibition by MK-801. Neuroreport 11, 3209-3212. (IF= 2,696; Q2)

    10.  Marti M, Paganini F, Stocchi S, Bianchi C, Beani L and Morari M (2001) Presynaptic group I and II metabotropic glutamate receptors oppositely modulate striatal acetylcholine release. Eur. J. Neurosci. 14, 1181-1184. (IF= 3,919; Q2)

    11.  Marti M, Guerrini R, Beani L, Bianchi C and Morari M (2002) Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat. Neuroscience 112, 153-160. (IF= 3,457; Q2)

    12.  Calò G, Rizzi A, Rizzi D, Bigoni R, Guerrini R, Marzola G, Marti M, McDonald J, Morari M, Lambert DG, Salvatori S and Regoli D (2002) [Nphe1, Arg14, Lys 15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br. J. Pharmacol. 136, 303-311. (IF= 3,45; Q1)

    13.  Pisani A, Bonsi P, Catania MV, Giuffrida R, Morari M, Marti M, Centonze D, Bernardi G, Kingston AE and Calabresi P (2002) Metabotropic glutamate 2, mGlu2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurones, J. Neurosci. 22, 6176-6185. (IF= 8,045; Q1)

    14.  Siniscalchi A, Rodi D, Morari M, Marti M, Cavallini S, Marino S, Beani L and Bianchi C (2002) Direct and in direct inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro. Br. J. Pharmacol. 136, 1178-1184. (IF= 3,45; Q1)

    15.  Marti M, Mela F, Bianchi C, Beani L and Morari M (2002) Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo. Opposite role for D1 and D2 receptors. J. Neurochem. 83, 635-644. (IF= 4,969; Q1)

    16.  Marti M, Stocchi S, Paganini F, Mela F, De Risi C, Calò G, Guerrini R, Barnes TA, Lambert DG, Beani L, Bianchi C and Morari M (2003) Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. Br. J. Pharmacol. 138, 91-98. (IF= 3,611; Q1)

    17.  Marti M, Paganini F, Stocchi S, Mela F, Beani L, Bianchi C and Morari M (2003) Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group II metabotropic and NMDA receptors J. Neurochem. 84, 792-802. (IF= 4,825; Q1)

    18.  Calabresi P, Marti M, Picconi B, Saulle E, Centonze D, Pisani F and Bernardi G (2003) Complementary mechanisms for the neuroprotective effects of lamotrigine and remacemide in striatal neurons. Exp. Neurol. 182, 461-469. (IF=3,676; Q1)

    19.  Marti M, Mela F, Ulazzi L, Hanau S, Stocchi S, Paganini F, Beani L, Bianchi C and Morari M (2003) Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington’s disease. Eur. J. Neurosci. 18, 759-767. (IF= 3,872; Q2)

    20.  Saulle E, Gubellini P, Picconi B, Centonze D, Tropepi D, Pisani A, Morari M, Marti M, Rossi L, Papa M, Bernardi G and Calabresi P (2004) Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington’s disease. Mol. Cell. Neurosi. 25, 9-20. (IF= 3,789; Q2)

    21.  Mela F, Marti M, Ulazzi L, Vaccari E, Zucchini S, Trapella C, Salvadori S, Beani L, Bianchi C and Morari M (2004) Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex. Eur. J. Neurosci. 19, 1317-1324. (IF= 3,82; Q2)

    22.  Marti M, Mela F, Veronesi C, Guerrini R, Salvadori S, Federici M, Mercuri NB, Rizzi A, Franchi G, Beani L, Bianchi C and Morari M (2004) Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J. Neurosci. 24, 6659-6666. (IF= 7,907; Q1)

    23.  Marti M, Mela F, Guerrini R, Calò G, Bianchi C and Morari M (2004) Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J. Neurochem. 91, 1501-1504. (IF= 4,824; Q1)

    24.  Marti M, Manzalini M, Fantin M, Bianchi C, Della Corte L and Morari M (2005) Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra and endogenous striatal substance P and dopamine. J. Neurochem. 93, 195-205. (IF= 4,604; Q1)

    25.  Cavallini S, Marti M, Marino S, Selvatici R, Beani L, Bianchi C and Siniscalchi A (2005) Effects of chemical ischemia in cerebral cortex slices. Focus on nitric oxide. Neurochem. Int. 47, 482-490. (IF= 2,994; Q2)

    26.  Marti M, Mela F, Fantin M, Zucchini S, Brown JM Witta J, Di Benedetto M, Buzas B, Reinscheid RK, Salvadori S, Guerrini R, Romualdi P, Candeletti S, Simonato M, Cox BM and Morari M (2005) Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson’s disease. J. Neurosci. 25, 9591-9601. (IF= 7,506; Q1)

    27.  Mela F, Marti M, Fiorentini C, Missale C and Morari M (2006) Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: role of P/Q-type high voltage activated Ca++ channels and endogenous dopamine. Mol. Cell. Neurosci 31, 284-292. (IF= 4,607; Q2)

    28.  Mela F, Marti M, Dekundy A, Danysz W, Morari M and Cenci MA (2007) Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson´s disease. J. Neurochem. 101, 483-497. (IF= 4,451; Q1)

    29.  Marti M, Trapella C, Viaro R and Morari M (2007) The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J. Neurosci. 27, 1297-1307. (IF= 7,49; Q1)

    30.  Fantin M, Marti M, Auberson YP and Morari M (2007) NR2A and NR2B subunit containing NMDA receptors differentially regulate striatal output pathways. J. Neurochem 103, 2200-2211. (IF= 4,451; Q1)

    31.  Esposito E, Fantin M, Marti M, Drechsler M, Paccamiccio L, Mariani P, Sivieri E, Menegatti E, Morari M and Cortesi R (2008) Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm. Res. 30, 430-438. (IF= 1,898; Q1)

    32.  Viaro R, Sanchez-Pernaute R, Marti M, Trapella C, Isacson O. and Morari M (2008) Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiol. Dis. 30, 340-348. (IF= 4,852; Q1)

    33.  Mabrouk OS, Volta M, Marti M and Morari M (2008) Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats. New insights into the role of delta receptors in parkinsonism. J. Neurochem. 107, 1647-1659. (IF= 4,5; Q1)

    34.  Marti M, Trapella C. and Morari M (2008) The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway. Positive interaction with L-DOPA. J. Neurochem. 107, 1683-1696. (IF= 4,5; Q1)

    35.  Marti M, Viaro R, Guerrini R, Franchi G and Morari M (2009) Nociceptin/orphanin FQ modulates motor behavior and primary motor cortex output through receptors located in substantia nigra reticulata. Neuropsychopharmacology 34, 341-355. (IF= 6,993; Q1)

    36.  Mabrouk OS, Marti M, Salvadori S and Morari M (2009) The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway. Neuroscience 164, 360-369. (IF= 3,292; Q2)

    37.  Mabrouk OS, Marti M and Morari M (2010) Endogenous nociceptin/orphanin FQ contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice. Neuroscience 166, 40-48. (IF= 3,215; Q2)

    38.  Viaro R, Marti M and Morari M (2010) Dual motor response to L-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: paradoxical inhibition is relieved by D2/D3 receptor blockade. Exp. Neurol. 223, 473-484. (IF= 4,436; Q1)

    39.  Volta M, Marti M, McDonald J, Molinari S, Camarda V, Pelà M, Trapella C and Morari M (2010) Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-Cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4). Peptides 31, 1194-1204. (IF= 2,654; Q2)

    40.  Marti M, Sarubbo S, Latini F, Cavallo M, Eleopra R, Biguzzi S, Lettieri C, Conti C, Simonato M, Zucchini S, Quatrale R, Sensi M, Candeletti S, Romualdi P and Morari M (2010) Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson’s disease. Mov. Disord. 25, 1723-1732. (IF= 4,480; Q1)

    41.  Volta M, Mabrouk OS, Bido S, Marti M and Morari M (2010) Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson’s disease: a behavioral and neurochemical study in reserpinized mice. J. Neurochem. 115, 1543-1555. (IF= 4,337; Q1)

    42.  Rizzi A, Molinari S, Marti M, Marzola G, Calo' G (2011) Nociceptin/orphanin FQ receptor knockout rats: in vitro and in vivo studies. Neuropharmacology 60, 572-579. (IF= 4,814; Q1)

    43.  Volta M, Viaro R, Trapella C, Marti M, Morari M (2011) Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity. Exp. Neurol. 228,126-137. (IF= 4,699; Q1)

    44.  Bido S, Marti M and Morari M (2011) Amantadine attenuates levodopa-induced dyskinesias in mice and rats preventing accompanying rise in GABA nigral levels. J. Neurochem. 118,1043-1055. (IF= 4,061; Q1)

    45.  Mela F, Marti M, Bido S, Angela Cenci MA and Morari M (2012) In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. Neurobiol. Dis. 45, 573-582. (IF= 5,624; Q1)

    46.  Costa C, Sgobio C, Siliquini S, Tozzi A, Cantucci M, Ghiglieri V, Di Filippo M, Pendolino V, de Iure A, Marti M, Morari M, Spillantini MG, La Tagliata EC, Pascucci T, Puglisi-Allegra S, Gardoni F, Di Luca M, Picconi B and Calabresi P (2012) Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson’s disease. Brain, 135, 1884-1899 (IF= 9,915; Q1)

    47.  Buzzi A, Chikhladze M, Falcicchia C, Paradiso B, Lanza G, Soukupova M, Marti M, Morari M, Franceschetti S, Simonato M (2012) Loss of cortical GABA terminals in Unverricht-Lundborg disease. Neurobiol Dis. 47, 216-224. (IF= 5,624; Q1)

    48.  Marti M, Rodi D, Li Q, Guerrini R, Fasano S, Morella I, Tozzi A, Brambilla R, Calabresi P, Simonato M, Bezard E, and Morari M (2012) Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias J Neurosci 32: 16106-16119 (IF= 6,908; Q1)

    49.  Marti M, Mela F, Budri M, Volta M, Malfacini D, Molinari S, Zaveri NT, Ronzoni S, Petrillo P, Calò G, Morari M. (2013) Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111. Br. J. Pharmacol. 168: 863-879 doi: 10.1111/j.1476-5381.2012.02219.x. (IF= 4,99; Q1)

    50.  Viaro R, Calcagno M, Marti M, Borrelli E, Morari M. (2013) Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands. Neuropharmacology. 72: 126-138. (IF= 4,819; Q1)

    51.  Porras G, De Deurwaerdere P, Li Q, Marti M, Morgenstern R, Sohr R, Bezard E, Morari M, Meissner WG (2014) L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum. Sci Rep. Jan 16;4:3730. doi: 10.1038/srep03730. (IF= 5,58; Q1)

    52.  Vigolo A, Ossato A, Trapella C, Vincenzi F, Rimondo C, Seri C, Varani K, Serpelloni G and Marti M (2015) Novel halogenated derivates of JWH-018: behavioral and binding studies in mice. Neuropharmacology, 95: 68-82 doi:10.1016/j.neuropharm.2015.02.008. (IF= 5,11; Q1)

    53.  Ossato A, Vigolo A, Trapella C, Seri C , Rimondo C, Serpelloni G, Marti M, (2015) JWH-018 impairs sensorimotor functions in mice, Neuroscience, 300: 174-188 doi: http://dx.doi.org/10.1016/j.neuroscience. 2015.05.021(IF= 3,357; Q2)

    54.  De Luca MA, Bimpisidis Z, Melis M, Marti M, Caboni P, Valentini V, Margiani G, Pintori N, Polis I, Marsicano G, Parsons LH, Di Chiara G. (2015) Stimulation of in vivo dopamine transmission and intravenous self-administration in rats and mice by JWH-018, a Spice cannabinoid. Neuropharmacology, 99: 705-714 doi: 10.1016/j.neuropharm.2015.08.041. (IF= 5,11; Q1)

    55.  Ossato A, Canazza I, Trapella C, Vincenzi F, De Luca MA, Rimondo C, Varani K, Borea PA, Serpelloni G, Marti M. (2016) Effect of JWH-250, JWH-073 and their interaction on "tetrad", sensorimotor, neurological and neurochemical responses in mice. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 67: 31-50 (IF= 3,68; Q1).

    56.  Miliano C, Serpelloni G, Rimondo C, Mereu M, Marti M, De Luca MA (2016) Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Frontiers in Neuroscience. 10:153. doi:10.3389/fnins.2016.00153 (IF= 3.398; Q2)

    57.  Barbieri M, Ossato A, Canazza I, Trapella C, Borelli AC, Beggiato S, Rimondo C, Serpelloni G, Ferraro L and Marti M. (2016) Synthetic cannabinoid JWH-018 and its halogenated derivatives JWH-018-Cl and JWH-018-Br impair Novel Object Recognition in mice: behavioral, electrophysiological and neurochemical evidence. Neuropharmacology, 109: 254-269 (IF= 5,11; Q1)

    58.  Canazza I, Ossato A, Trapella C, Fantinati A, De Luca MA, Margiani G, Vincenzi F, Rimondo C, Di Rosa F, Gregori A, Varani K, Borea PA, Serpelloni G and Marti M. (2016) Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on “tetrad”, sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies. Psychopharmacology, 233: 3685-3709 (IF= 3.54; Q1)

    59.  Fantinati A, Ossato A, Bianco S, Canazza I, De Giorgio F, Trapella C, and Marti M. (2017) 1‐cyclohexyl‐x‐methoxybenzene derivatives, novel psychoactive substances seized on the internet market. Synthesis and in vivo pharmacological studies in mice. Hum Psychopharmacol Clin Exp. 32(3). doi: 10.1002/hup.2560 (IF= 2.44; Q2).

    60.  Canazza I, Ossato A, Vincenzi F, Gregori A, Di Rosa F, Nigro F, Rimessi A, Pinton P, Varani K, Borea PA and Marti M (2017) Pharmaco-toxicological effects of the novel third-generation fluorinate synthetic cannabinoids, 5F-ADBINACA, AB-FUBINACA and STS-135 in mice. In vitro and in vivo studies. Hum Psychopharmacol Clin Exp. 32(3). doi: 10.1002/hup.2601 (IF= 2.44; Q2).

    61.  Montesano C, Vannutelli G, Fanti F, Gregori A, Togna AR, Canazza I, Marti M, and Sergi M (2017) Identification of MT-45 metabolites: in silico prediction, in vitro incubation with rat hepatocytes and in vivo confirmation. Journal of Analytical Toxicology. 41, 8: 688–697. doi: 10.1093/jat/bkx058. [Epub ahead of print]. (IF= 2.4; Q2)

    62.  Giannotti G, Canazza I, Caffino L, Bilel S, Ossato A, Fumagalli F and Marti M (2017) The cathinones MDPV and α-PVP elicit different behavioral and molecular effects following acute exposure. Neurotoxicity Research. 32: 594-602 DOI: 10.1007/s12640-017-9769-y (IF= 3.186; Q2)

    63.  Ossato A, Uccelli L, Bilel S, Canazza I, Di Domenico G, Pasquali M, Pupillo G, De Luca MA, Boschi A, Vincenzi F, Rimondo C, Beggiato S, Ferraro L, Varani K, Borea PA, Serpelloni G, De-Giorgio F and Marti M (2017) Psychostimulant effect of the synthetic cannabinoid jwh-018 and akb48. behavioural, neurochemical and dat scan imaging studies in mice. Frontiers in Psychiatry. 4;8:130. doi: 10.3389/fpsyt.2017.00130. (IF= 2.857; Q2)

    64.  Beggiato S, Borelli AC, Borroto-Escuela D, Corbucci I, Tomasini MC, Marti M, Antonelli T, Tanganelli S, Fuxe K, Ferraro L. (2017) Cocaine modulates allosteric D2-σ1 receptor-receptor interactions on dopamine and glutamate nerve terminals from rat striatum. Cell Signal. 18; 40: 116-124. doi: 10.1016/j.cellsig.2017.09.007. (IF= 3.487; Q2)

    65.  Foti F#, Marti M#, Ossato A, Bilel S, Sangiorgi E, Botrè F, Bruna Cerbelli B, Baldi A, De-Giorgio F. (2018) Phenotypic effects of chronic and acute use of methiopropamine in a mouse model. International Journal of Legal Medicine. 2018 Jul 28. doi: 10.1007/s00414-018-1891-8. (IF= 2.094; Q1)

    66.  Ossato A, Bilel S, Gregori A, Talarico A, Trapella C, Gaudio RM, De-Giorgio F, Tagliaro F, Neri M, Fattore L, Marti M. (2018) Neurological, sensorimotor and cardiorespiratory alterations induced by methoxetamine, ketamine and phencyclidine in mice. Neuropharmacology. 141: 167-180. (IF= 4.367; Q1)

    67.  Frisoni P, Bacchio E, Bilel S, Talarico A, Gaudio RM, Barbieri M, Neri M and Marti M (2018) Novel Synthetic Opioids: The Pathologist’s Point of View. Brain Sci. 8(9), 170; https://doi.org/10.3390/brainsci8090170 (IF= 2.786; Q2)

    68.  Marti M, Neri M, Bilel S, Di Paolo M, La Russa R, Ossato A, Turillazzi E. (2019) MDMA alone affects sensorimotor and prepulse inhibition responses in mice and rats. Tips in the debate on potential MDMA unsafety in human activity. Forensic Toxicology 37 (1): 132-144. (IF= 2.945; Q2)

    69.  De-Giorgio F, Bilel S, Ossato A, Tirri M, Arfè R, Foti F, Serpelloni G, Frisoni P, Neri M and Marti M. (2019) Acute and repeated administration of MDPV increases aggressive behaviour in mice: forensic implications. International Journal of Legal Medicine. 133: 1797–1808 https://doi.org/10.1007/s00414-019-02092-3 (IF= 2.222; Q1)

    70.  Bilel S#, Tirri M#, Arfè R, Stopponi S, Soverchia L, Ciccocioppo R, Frisoni P, Strano-Rossi S, Miliano C, De-Giorgio F, Serpelloni G, Fantinati A, De Luca MA, Neri M and Marti M (2019) Pharmacological and behavioural effects of the synthetic cannabinoid AKB48 in rats. Front. Neurosci. 13:1163. doi: 10.3389/fnins.2019.01163 (IF= 3.707; Q2)

    71.  Miliano C, Marti M, Pintori N, Castelli MP, Tirri M, Arfè R, De Luca M (2019) Neurochemical and behavioral profiling in male and female rats of the psychedelic agent 25I-NBOME. Front. Pharmacol. 10:1406. doi: 10.3389/fphar.2019.01406 (IF= 4.225; Q1)

    72.  Neri M, Fabbri M, D'Errico S, Di Paolo M, Frati P, Gaudio R M, La Russa R, Maiese A, Marti M, Pinchi E, Turillazzi E, and Fineschi V (2019) Regulation of miRNAs as new tool for cutaneous vitality lesions demonstration in ligature marks in deaths by hanging. Scientific Reports 27;9(1):20011. doi: 10.1038/s41598-019-56682-7. (IF= 3.998; Q1)

    73.  Bilel S, Tirri M, Arfè R, Ossato A, Trapella C; Serpelloni G; Neri M; Fattore L and Marti M (2020) Novel halogenated synthetic cannabinoids impair sensorimotor functions in mice. Neurotoxicology 76 17–32. https://doi.org/10.1016/j.neuro.2019.10.002 (IF= 3.105; Q2)

    74.  De-Giorgio F, Bilel S, Ossato A, Tirri M, Arfè R, Foti F, Serpelloni G, Frisoni P, Neri M and Marti M. (2020) Reply to ‘MDPV induced aggression in humans not established’. International Journal of Legal Medicine (2020) 134: 263–265. https://doi.org/10.1007/s00414-019-02176-0. (IF= 2.222; Q1)

    75.  Lenzi M, Cocchi V, Cavazza L, Bilel S, Hrelia P, Marti M (2020) Genotoxic properties of synthetic cannabinoids on TK6 human cells by flow cytometry. International Journal of Molecular Sciences 21, 1150 (IF= 4.556; Q1)

    76.  Kamakolanu UG, Meyer ME, Yasuda D, Polgar WE, Marti M, Mercatelli D, Pisanò CA, Brugnoli A, Morari M, Zaveri NT. (2020) Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models. J Med Chem. 2020 Feb 3. doi: 10.1021/acs.jmedchem.9b02134. (IF= 6.205; Q1)

    77.  Morbiato E, Bilel S, Tirri M, Arfè R, Fantinati A, Savchuk S, Appolonova S, Frisoni P, Tagliaro F, Neri M, Grignolio S, Bertolucci C and Marti M (2020) Potential of the zebrafish model for the forensic toxicology screening of NPS: a comparative study of the effects of APINAC and Methiopropamine on the behavior of zebrafish larvae and mice. Neurotoxicology, 78: 36-46, https://doi.org/10.1016/j.neuro.2020.02.003 (IF= 3.105; Q2)

    78.  De-Giorgio F, Bilel S, Tirri M, Arfè R, Trapella C, Camuto C, Foti F, Frisoni P, Neri M, Botrè F, Marti M (2020) Methiopropamine and its acute behavioral effects in mice: is there a grey zone in New Psychoactive Substances users? Int J Legal Med. Sep;134(5):1695-1711. doi: 10.1007/s00414-020-02302-3. Epub 2020 May 1. (IF= 2.222; Q1)

    79.  Bilel S, Azevedo NJ, Arfè R, Tirri M, Gregori A, Serpelloni G, De-Giorgio F, Frisoni P, Neri M, Calo' G and Marti M (2020) In vitro and in vivo pharmacological characterization of the synthetic opioid MT-45. Neuropharmacology. Jul;171:108110. doi: 10.1016/j.neuropharm.2020.108110. Epub 2020 Apr 25. (IF= 4.431; Q1)

    80.  Mestria S, Odoardi S, Federici S, Bilel S, Tirri M, Marti M and Strano Rossi S (2020) Metabolism study of N-methyl 2-amino Indane (NM2AI) and determination of metabolites in biological samples by LC-HRMS. J Anal Toxicol. 2020 Aug 29:bkaa111. doi: 10.1093/jat/bkaa111. Online ahead of print. (IF= 3.513; Q1)

    81.  Camuto C, Pellegrini S, De Giorgio F, de la Torre X, Marti M, Mazzarino M, Botrè F (2020) Urinary excretion profile of methiopropamine in mice following intraperitoneal administration: a liquid chromatography-tandem mass spectrometry investigation. Drug Testing and Analysis. 2020 Jul 17. doi: 10.1002/dta.2900. Epub ahead of print. PMID: 32678963. (IF= 2.903; Q2)

    82.  Tirri M, Ponzoni L, Bilel S, Arfè R, Braida D, Sala M, Marti M (2020) Acute DOB and PMA Administration Impairs Motor and Sensorimotor Responses in Mice and Causes Hallucinogenic Effects in Adult Zebrafish. Brain Sci. 2020 Aug 24;10(9):E586. doi: 10.3390/brainsci10090586. (IF= 3.332; Q2)

    83.  Fattore L, Marti M, Mostallino R, Castelli M.P. (2020) Sex and Gender Differences in the Effects of Novel Psychoactive Substances. Brain Sci. 2020, 10(9), 606; https://doi.org/10.3390/brainsci10090606 (IF= 3.332; Q2)

    84.  Chieffi C, Camuto C, De-Giorgio F, de la Torre X, Diamanti F, Mazzarino M, Trapella C, Marti M & Botrè (2020) Metabolic profile of the synthetic drug 4,4′-dimethylaminorex in urine by LC–MS-based techniques: selection of the most suitable markers of its intake. Forensic Toxicol (2020). https://doi.org/10.1007/s11419-020-00544-9 (IF= 2.945; Q2)

    85.  Cocchi V, Gasperini S, Hrelia P, Tirri M, Marti M* and Lenzi M* (2020) Novel Psychoactive Phenethylamines: Impact on Genetic Material. International Journal of Molecular Sciences 21(24), 9616; https://doi.org/10.3390/ijms21249616 (IF= 4.556; Q1)